Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Fresenius SE KGaAXSWX:FRE 68 Future 3-5Y EPS without NRI Growth Rate is 6.01 as of Aug. 01, 2026. GuruFocus rates XSWX:FRE with a GF Score™ of 68/100 and a GF Value™ of CHF33.35 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 197 Healthcare Providers & Services companies, Fresenius SE KGaA ranks worse than 87.82% on this metric.
Future 3-5Y EPS without NRI Growth Rate is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.
As of today, Fresenius SE KGaA's Future 3-5Y EPS without NRI Growth Rate is 6.01.
Fresenius SE KGaA (XSWX:FRE) Future 3-5Y EPS without NRI Growth Rate Explanation
Future 3-5Y EPS without NRI Growth Rate s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.
Fresenius SE KGaA Future 3-5Y EPS without NRI Growth Rate Related Terms
XSWX:FRE vs HCA, THC, DVA: Future 3-5Y EPS without NRI Growth Rate Comparison
For the Medical Care Facilities subindustry, Fresenius SE KGaA's Future 3-5Y EPS without NRI Growth Rate, along with its competitors' market caps and Future 3-5Y EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fresenius SE KGaA Future 3-5Y EPS without NRI Growth Rate vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Fresenius SE KGaA's Future 3-5Y EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Fresenius SE KGaA's Future 3-5Y EPS without NRI Growth Rate falls into.
What does a Future 3-5Y EPS without NRI Growth Rate of 6.01 mean?
Fresenius SE KGaA (XSWX:FRE) has a Future 3-5Y EPS without NRI Growth Rate of 6.01 as of Aug. 01, 2026. EPS Growth Rate (Future 3Y To 5Y Estimate) is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period. View historical data for Fresenius SE KGaA and its competitors. According to the industry distribution chart, Fresenius SE KGaA ranks #173 out of 197 companies in the Healthcare Providers & Services industry, placing it in the top 87.8%.
Is Fresenius SE KGaA's Future 3-5Y EPS without NRI Growth Rate too high?
Fresenius SE KGaA's current Future 3-5Y EPS without NRI Growth Rate is 6.01. The Healthcare Providers & Services industry median Future 3-5Y EPS without NRI Growth Rate is 16.40. Fresenius SE KGaA's value of 6.01 is 63.4% below this industry median. Based on the distribution chart, Fresenius SE KGaA ranks #173 out of 197 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Fresenius SE KGaA has a GF Score™ of 68/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Fresenius SE KGaA's Future 3-5Y EPS without NRI Growth Rate compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Fresenius SE KGaA ranks #173 out of 197 companies for Future 3-5Y EPS without NRI Growth Rate. This places Fresenius SE KGaA in the lower half of its industry. The industry median Future 3-5Y EPS without NRI Growth Rate is 16.40. Fresenius SE KGaA's value of 6.01 is 63.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Future 3-5Y EPS without NRI Growth Rate for a Healthcare Providers & Services company?
The median Future 3-5Y EPS without NRI Growth Rate among Healthcare Providers & Services companies is 16.40, based on 197 companies in the industry. Companies in the top quartile (top 25%) have a Future 3-5Y EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, Future 3-5Y EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Fresenius SE KGaA's current Future 3-5Y EPS without NRI Growth Rate of 6.01 is 63.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Future 3-5Y EPS without NRI Growth Rate mean?
A high Future 3-5Y EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. EPS Growth Rate (Future 3Y To 5Y Estimate) is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period. View historical data for Fresenius SE KGaA and its competitors. For the Healthcare Providers & Services industry, the median Future 3-5Y EPS without NRI Growth Rate is 16.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fresenius SE KGaA's current Future 3-5Y EPS without NRI Growth Rate is 6.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fresenius SE KGaA stock overvalued right now?
Based on GuruFocus' analysis, Fresenius SE KGaA (XSWX:FRE) is currently considered Modestly Overvalued. The stock's GF Value™ is CHF33.35, compared to a current price of CHF40.44 — trading 21.3% above its estimated fair value. The current Future 3-5Y EPS without NRI Growth Rate is 6.01 and 63.4% below the Healthcare Providers & Services industry median of 16.40. Fresenius SE KGaA's overall GF Score™ is 68/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Future 3-5Y EPS without NRI Growth Rate calculated?
Future 3-5Y EPS without NRI Growth Rate is calculated from a company's financial statements. For Fresenius SE KGaA (XSWX:FRE), the current Future 3-5Y EPS without NRI Growth Rate is 6.01 as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fresenius SE KGaA (XSWX:FRE) Overvalued in 2026?
Based on GuruFocus' analysis, Fresenius SE KGaA stock appears to be overvalued.
The current stock price of CHF40.44 is trading 21.3% above its estimated GF Value™ of CHF33.35.
GuruFocus considers Fresenius SE KGaA to be Modestly Overvalued.
Key valuation signals for XSWX:FRE:
Future 3-5Y EPS without NRI Growth Rate: 6.01
GF Value™: CHF33.35 vs. price of CHF40.44 (21.3% above fair value)
Industry Position: 63.4% below the Healthcare Providers & Services median (#173 of 197)
No single metric tells the full story. See the XSWX:FRE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fresenius is a healthcare holding company based in Germany. The company owns a minority stake in dialysis service provider and equipment manufacturer Fresenius Medical Care. The Kabi segment manufactures intravenous drugs, nutrition products, infusion and transfusion therapies, and related pumps. The Helios segment operates private hospitals primarily in Germany and Spain.
68GF Score
Get the complete analysis for XSWX:FRE
Future 3-5Y EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:FRE has been successfully added to your 
